Evidence map›Paper›PMID 33176026›Full record

ArticleMedical physics2020

Technical Note: MRQy - An open-source tool for quality control of MR imaging data.

Amir Reza Sadri, Andrew Janowczyk, Ren Zhou, Ruchika Verma, Niha Beig, Jacob Antunes, Anant Madabhushi, Pallavi Tiwari, Satish E Viswanath

Abstract read
In one paragraph

Article in Medical physics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. aXonica: A support package for MRI based Neuroimaging.Biotechnology notes (Amsterdam, Netherlands) · 2024
    Article
  18. Article
  19. Article
  20. DSMRI: Domain Shift Analyzer for Multi-Center MRI Datasets.Diagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amir Reza SadriDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Andrew JanowczykDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Ren ZhouDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Ruchika VermaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Niha BeigDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Jacob AntunesDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Anant MadabhushiDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Pallavi TiwariDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.
Satish E ViswanathDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, 44106, USA.

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Computer-Assisted Histologic Evaluation of Cardiac Allograft RejectionR01HL151277 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MADABHUSHI, ANANT, MARGULIES, KENNETH BER · 2020 to 2023
$3.2M
Computerized histologic image predictor of cancer outcomeR01CA202752 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FELDMAN, MICHAEL D, GANESAN, SHRIDAR · 2016 to 2020
$3.1M
Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal CarcinomaR01CA220581 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI KOYFMAN, SHLOMO, LEWIS, JAMES · 2018 to 2023
$3.1M
Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung CancersR01CA216579 · NCI · EMORY UNIVERSITY · PI FU, PINGFU, LLOYD, MARK · 2018 to 2023
$3.1M
MR Fingerprinting and Computerized Decision Support for Prostate CancerR01CA208236 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GULANI, VIKAS, PONSKY, LEE EVAN · 2017 to 2022
$3.0M
Pathology Image Informatics Platform for visualization, analysis and managementU24CA199374 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GURCAN, METIN NAFI, MADABHUSHI, ANANT · 2015 to 2019
$2.9M
RadxTools for assessing tumor treatment response on imagingU01CA248226 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI TIWARI, PALLAVI, VISWANATH, SATISH EASWAR · 2020 to 2022
$1.4M
HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identificationU01CA239055 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JANOWCZYK, ANDREW ROBERT, MADABHUSHI, ANANT · 2019 to 2022
$1.0M
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear SlidesR43EB028736 · NIBIB · DIASCOPIC, LLC · PI MADABHUSHI, ANANT, SERIF, CARY · 2019 to 2019
$225k
Rad-path-omic tools for rectal cancer treatment evaluationF31CA216935 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI ANTUNES, JACOB · 2019 to 2020
$71k
BIOMEDICAL ENGINEERING RESEARCH FACILITIESC06RR012463 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI KUTINA, KENNETH L · 1997 to 1997
–
BLRD VA I01 BX004121BLRD VA IK6 BX006185Breast Cancer Research Program W81XWH-19-1-0668Clinical and Translational Science Collaborative of Cleveland UL1TR0002548Kidney Precision Medicine ProjectLung Cancer Research Program W81XWH-18-1-0440Lung Cancer Research Program W81XWH-20-1-0595National Heart, Lung and Blood Institute 1R01HL15127701A1National Institute for Biomedical Imaging and Bioengineering 1R43EB028736-01NCATS NIH HHS UL1 TR002548NCI NIH HHS 1F31CA216935-01A1NCI NIH HHS 1U01CA239055-01NCI NIH HHS 1U01CA248226-01NCI NIH HHS 1U24CA199374-01NCI NIH HHS F31 CA216935NCI NIH HHS R01 CA202752NCI NIH HHS R01CA202752-01A1NCI NIH HHS R01 CA208236NCI NIH HHS R01CA208236-01A1NCI NIH HHS R01 CA216579NCI NIH HHS R01CA216579-01A1NCI NIH HHS R01 CA220581NCI NIH HHS R01CA220581-01A1NCI NIH HHS U01 CA239055NCI NIH HHS U01 CA248226NCI NIH HHS U24 CA199374NCRR NIH HHS 1C06RR12463-01NCRR NIH HHS C06 RR012463NHLBI NIH HHS R01 HL151277NIBIB NIH HHS R43 EB028736Peer Reviewed Cancer Research Program W81XWH-16-1-0329Peer Reviewed Cancer Research Program W81XWH-18-1-0404Prostate Cancer Research Program W81XWH-15-1-0558Prostate Cancer Research Program W81XWH-20-1-0851VA Merit Review Award IBX004121AWallace H. Coulter Foundation Program
6 · The paper itself

Abstract

purposeThere is an increasing availability of large imaging cohorts [such as through The Cancer Imaging Archive (TCIA)] for computational model development and imaging research. To ensure development of generalizable computerized models, there is a need to quickly determine relative quality differences in these cohorts, especially when considering MRI datasets which can exhibit wide variations in image appearance. The purpose of this study is to present a quantitative quality control tool, MRQy, to help interrogate MR imaging datasets for: (a) site- or scanner-specific variations in image resolution or image contrast, and (b) imaging artifacts such as noise or inhomogeneity; which need correction prior to model development.

methodsUnlike existing imaging quality control tools, MRQy has been generalized to work with images from any body region to efficiently extract a series of quality measures (e.g., noise ratios, variation metrics) and MR image metadata (e.g., voxel resolution and image dimensions). MRQy also offers a specialized HTML5-based front-end designed for real-time filtering and trend visualization of quality measures.

resultsMRQy was used to evaluate (a) n = 133 brain MRIs from TCIA (7 sites) and (b) n = 104 rectal MRIs (3 local sites). MRQy measures revealed significant site-specific variations in both cohorts, indicating potential batch effects. Before processing, MRQy measures could be used to identify each of the seven sites within the TCIA cohort with 87.5%, 86.4%, 90%, 93%, 90%, 60%, and 92.9% accuracy and the three sites within the rectal cohort with 91%, 82.8%, and 88.9% accuracy using unsupervised clustering. After processing, none of the sites could be distinctively clustered via MRQy measures in either cohort; suggesting that batch effects had been largely accounted for. Marked differences in specific MRQy measures were also able to identify outlier MRI datasets that needed to be corrected for common acquisition artifacts.

conclusionsMRQy is designed to be a standalone, unsupervised tool that can be efficiently run on a standard desktop computer. It has been made freely accessible and open-source at http://github.com/ccipd/MRQy for community use and feedback.

Indexed as

ArtifactsMagnetic Resonance ImagingCohort StudiesHumansImage Processing, Computer-AssistedQuality Controlacquisition artifactsbatch effectsimaging variationsMRInoisequality control

Identifiers

PMID33176026
PMCPMC8176950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.